OakChart

Baxter International Inc

BAXHealthcare·Medical Instruments & Supplies·USA·Large·NYSE·Nov 11 • 8:07 AM ET

26.35-0.07 (-0.26%)
2026-11-11 15:18 CET
Market cap
13,668.33 USD m
Revenue, TTM
11,611.00 USD m
Net income, TTM
-705.00 USD m
Free cash flow, TTM
1,137.00 USD m
EPS diluted, TTM
-1.38
P/E
-
Compare

Price

BAX against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.0011.3M22.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BAXclose 26.3520-day 25.2650-day 24.54200-day 21.5826.35

12.2% under 30.00 on 30 Jul 2026. Last 15 sessions, 20.4% high to low

Profile

BAX
52-week range, 74% of the way up
15.7330.00

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment sells connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment focuses on the sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

IndexS&P 500, RUI
Employees37500
IPOMay 16, 1961
Beta0.64
ATR, 14d1.01
Rel volume0.05
Short float4.61%
Insider own0.64%
Inst own108.53%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap13.63B
Enterprise Value19.64B
Income-705.00M
Sales11.61B
Book/sh12.57
Cash/sh3.82
Dividend Est.0.04 (0.15%)
Dividend TTM0.04 (0.15%)
Dividend Ex-DateNov 27, 2026
Dividend Gr. 3/5Y-23.25% -11.35%
Payout-
Employees37500
IPOMay 16, 1961

Ratios

P/E-
Forward P/E12.92
PEG-
P/S1.17
P/B2.10
P/C6.90
P/FCF11.99
EV/EBITDA11.96
EV/Sales1.69
Quick Ratio1.19
Current Ratio1.79
Debt/Eq1.23
LT Debt/Eq1.10
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.38
EPS next Y2.04
EPS next Q0.60
EPS this Y-4.81%
EPS next Y-3.03%
EPS next 5Y-0.65%
EPS past 3/5Y24.78% -
Sales past 3/5Y-8.14% -0.75%
EPS Y/Y TTM-164.67%
Sales Y/Y TTM5.33%
EPS Q/Q3130.86%
Sales Q/Q4.97%
EarningsOct 29 BMO
EPS/Sales Surpr.11.93% 2.34%

Ownership

Insider Own0.64%
Insider Trans0.00%
Inst Own108.53%
Inst Trans1.69%
ROA-3.06%
ROE-9.01%
ROIC-5.16%
Gross Margin31.92%
Oper. Margin5.92%
Profit Margin-6.07%
SMA204.32%
SMA507.40%
SMA20022.11%
Trades-

Technical

Shs Outstand517.35M
Shs Float514.04M
Short Float4.61%
Short Ratio3.63
Short Interest23.67M
52W High30.00 -12.17%
52W Low15.73 67.51%
Volatility4.66% 4.19%
ATR (14)1.01
RSI (14)58.70
Beta0.64
Rel Volume0.05
Avg Volume6.51M
Volume15,018

Performance

Perf Week-0.57%
Perf Month5.87%
Perf Quarter-2.59%
Perf Half Y52.22%
Perf YTD37.89%
Perf Year44.38%
Perf 3Y-19.71%
Perf 5Y-66.71%
Perf 10Y-43.72%
Recom2.94
Target Price26.09
Prev Close26.42
Price26.35
Change %-0.26%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2026InitiatedWWolfe ResearchPeer Perform
Oct 07, 2026InitiatedBBarclaysUnderweight$20-24.1%
Jul 31, 2026UpgradeCCitigroupSell → Neutral$28+6.3%
May 28, 2026DowngradeCCitigroupNeutral → Sell$17-35.5%
Oct 31, 2025DowngradeAArgusBuy → Hold
Aug 04, 2025DowngradeSStifelBuy → Hold$25-5.1%
Aug 01, 2025DowngradeGGoldmanBuy → Neutral$25-5.1%
Feb 26, 2025ResumedGGoldmanBuy$42+59.4%
Feb 24, 2025UpgradeAArgusHold → Buy
Feb 20, 2025ResumedBBarclaysOverweight$39+48.0%

Peers

Mkt cap
TickerCompanyMkt cap
BDXBecton Dickinson & Co57.20B
ICUIICU Medical Inc4.59B
SOLVSolventum Corp15.10B
TFXTeleflex Incorporated6.06B
MMSIMerit Medical Systems Inc5.22B
SYKStryker Corp122.20B
MDTMedtronic Plc128.68B
STESteris Plc24.57B
CAHCardinal Health Inc63.56B
IARTIntegra Lifesciences Holdings Corp1.17B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
STEPHEN N. OESTERLE REV TRUSTFormer AffiliateMay 18 '26Proposed Sale17.7536,347645,236May 18 04:57 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VOOVanguard S&P 500 ETFAUM: 1054.75B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
RSPInvesco S&P 500 Equal Weight ETFAUM: 104.94B
IVViShares Core S&P 500 ETFAUM: 871.38B
SPYSPDR S&P 500 ETF TrustAUM: 793.23B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.35B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B

News

latest 14 of 206
  • Baxters shares fall as Q3 probability dips despite revenue growth (Medical Device Network)
  • Baxter International Inc. stock underperforms Thursday when compared to competitors (MarketWatch) -7.70%
  • Baxter Beats And Raises Again As Turnaround Firms, But Margin Pressure, A New FDA Warning Letter And 2027 Headwinds Temper The Setup (Earnings Whispers)
  • Baxter: Q3 Earnings Snapshot (Associated Press)
  • Baxter Reports Third-Quarter 2026 Results (Business Wire)
  • Loading…
  • Baxter Must Prove Its Turnaround Holds Without A Tariff Refund Cushion (Earnings Whispers)
  • Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors (Business Wire)
  • Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
  • Baxter Releases Inaugural Connected Hospital Report (Business Wire)
  • Microsoft Leads S&P 500 Stocks Going Nowhere (GuruFocus.com)
  • Baxter hires new CFO with visa contingency (CFO Dive)
  • Baxter hires CFO from Smith & Nephew (MedTech Dive)
  • Baxter Appoints John Rogers Chief Financial Officer (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-290.5800.5180.5702,9762,90813
2026Q22026-07-300.5600.3670.2432,9602,79611
2026Q12026-04-300.3700.311-0.0292,7012,61512
2025Q42026-02-120.3600.536-2.1602,9742,82514
2025Q32025-10-300.6900.5980.0182,8352,87713
2025Q22025-07-310.5900.6100.2182,8102,82313
2025Q12025-05-010.5500.4840.2452,6252,58813
2024Q42025-02-200.5800.528-1.0022,7532,67312
2024Q32024-11-080.4900.7770.2732,6993,84713
2024Q22024-08-060.6800.662-0.6163,8123,75514
2024Q12024-05-020.6500.6070.0733,5923,55413
2023Q42024-02-080.8800.8640.4993,8853,80613
2023Q32023-11-020.8200.667-0.7533,7083,69711
2023Q22023-07-270.6600.600-0.2793,7073,78614
2023Q12023-04-270.5900.4940.0873,6493,60113
2022Q42023-02-090.8800.9400.3573,8873,76712

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY2.4802.4311.28810,56110,557
2018FY3.0503.0012.83211,12711,083
2019FY3.3103.4141.92911,36211,362
2020FY3.0903.0562.13211,67311,582
2021FY3.6103.5972.52812,78412,570
2022FY3.5003.559-4.82715,11314,998
2023FY2.6002.587-0.44714,81314,741
2024FY1.8901.838-1.27310,63610,557
2025FY2.2102.366-1.87011,24411,083
2026FY-2.104--11,725
2027FY-2.040--11,969
2028FY-2.167--12,244

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0212903,0873,0563,123
2026Q4S2026-10-2912803,0793,0343,103
2026Q4S2026-10-1712003,0463,0343,076
2026Q4S2026-10-1612103,0463,0343,076
2026Q4S2026-10-1311103,0463,0343,076
2026Q4S2026-08-1311803,0463,0343,076
2026Q4S2026-08-0311803,0463,0343,076
2026Q4S2026-07-3111703,0433,0003,076
2026Q4S2026-07-3011703,0393,0003,076
2026Q4S2026-07-2711003,0042,9663,040
2026Q4S2026-07-1410003,0032,9663,040
2026Q4S2026-05-2611063,0032,9663,040
2026Q4S2026-05-1211053,0042,9663,040
2026Q4S2026-04-3011053,0042,9663,040

Estimate history

EPS, annual1.2882.8321.9292.1322.528-4.827-0.447-1.273-2.055-1.38
Period201720182019202020212022202320242025TTM
EPS, quarterly0.273-1.0020.2450.2180.018-2.16-0.0290.2430.565
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10561110991136211673127841450610360106361124411611
Period201720182019202020212022202320242025TTM
Sales, quarterly269927532625281028352974270129602976
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual541.477512.999506.155504.915501.615501.615507.633510.927514.281517.348
Period201720182019202020212022202320242025MRQ
Shares, quarterly510.462510.927513.08513.498513.946514.281516.447516.996517.348
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue11,611.0011,244.0010,636.0010,360.0014,506.0012,784.0011,673.0011,362.0011,099.00
Cost of Goods Sold Incl. D&A7,905.007,535.006,782.006,373.008,978.007,564.006,997.006,475.006,276.00
Gross Profit3,706.003,709.003,854.003,987.005,528.005,220.004,676.004,887.004,823.00
Selling, General and Administrative Excl. Other3,019.003,016.003,167.003,084.003,888.003,139.002,858.002,979.003,071.00
Research and Development483.00503.00510.00508.00599.00529.00495.00542.00621.00
Other Operating Expense0.000.000.000.000.00-2.000.000.000.00
Operating Income687.00693.00687.00903.001,640.002,083.001,818.001,908.001,752.00
Interest Expense291.00284.00402.00502.00421.00152.00152.00111.0089.00
Unusual Expense851.001,170.00711.00195.003,817.00446.00258.00157.00145.00
Net Income Before Taxes-187.00-505.00-289.00242.00-2,650.001,477.001,292.00970.001,617.00
Income Taxes432.00395.0037.0061.004.00182.00182.00-41.0065.00
Consolidated Net Income-619.00-900.00-326.00181.00-2,654.001,295.001,110.001,011.001,552.00
Net Income From Continuing Operations-619.00-900.00-337.00174.00-2,666.001,284.001,102.001,001.001,552.00
Net Income-705.00-1,054.00-649.00-226.00-2,433.001,284.001,102.001,001.001,546.00
EPS (Recurring)-0.21-0.46-0.30-0.180.473.142.482.143.02
EPS (Basic, Before Extraordinaries)-1.38-2.05-1.27-0.45-4.832.562.171.972.90
EPS (Diluted)-1.38-2.05-1.27-0.45-4.832.532.131.932.83
EBITDA1,642.001,674.001,684.001,887.003,020.002,973.002,641.002,697.002,523.00
Non-Operating Income (Expense)268.00256.00137.0036.00-52.00-8.00-116.00-670.0099.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense89.78104.00106.00105.00119.00110.0077.0052.0054.00
Price To Earnings Ratio--127.17--33.9637.6342.0222.06
Price To Sales Ratio1.070.871.401.891.773.413.553.823.24
Gross Margin31.9232.9936.2438.4838.1140.8340.0643.0143.45
Operating Margin5.926.166.468.7211.3116.2915.5716.7915.79
Net Margin-6.07-9.37-6.10-2.18-16.7710.049.448.8113.93
Shares Outstanding517.35514.28510.93507.63501.62501.62504.91506.15513.00
Market Capitalization13,668.3313,668.3314,888.7519,613.1525,695.0542,979.4940,988.0442,692.6935,025.52

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2,976.002,960.002,701.002,974.002,835.002,810.002,625.002,753.00
Cost of Goods Sold Incl. D&A1,985.001,967.001,849.002,104.001,897.001,842.001,696.001,769.00
Gross Profit991.00993.00852.00870.00938.00968.00929.00984.00
Selling, General and Administrative Excl. Other755.00773.00738.00753.00747.00773.00750.00810.00
Research and Development118.00125.00124.00116.00115.00134.00138.00131.00
Other Operating Expense0.000.000.000.00-3.000.00-4.000.00
Operating Income236.00220.00114.00117.00194.00195.00183.00174.00
Interest Expense73.0075.0076.0067.0067.0070.0084.0098.00
Unusual Expense-189.0051.00106.00883.0074.0023.00181.00603.00
Net Income Before Taxes417.00158.00-6.00-756.00121.00133.00-3.00-521.00
Income Taxes119.0023.0011.00279.00172.0011.00-67.00-33.00
Consolidated Net Income298.00135.00-17.00-1,035.00-51.00122.0064.00-488.00
Net Income From Continuing Operations298.00135.00-17.00-1,035.00-51.00122.0064.00-490.00
Net Income294.00126.00-15.00-1,110.009.00112.00126.00-512.00
EPS (Recurring)0.310.310.11-0.960.120.250.49-0.18
EPS (Basic, Before Extraordinaries)0.570.24-0.03-2.160.020.220.25-1.00
EPS (Diluted)0.570.24-0.03-2.160.020.220.25-1.00
EBITDA475.00459.00351.00357.00431.00452.00430.00419.00
Non-Operating Income (Expense)65.0064.0062.0077.0068.0031.0079.006.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense26.0746.61-14.2231.3232.3932.397.90-
Price To Earnings Ratio-------127.17
Price To Sales Ratio1.070.960.760.871.061.431.481.16
Gross Margin33.3033.5531.5429.2533.0934.4535.3935.74
Operating Margin7.937.434.223.936.846.946.976.32
Net Margin9.884.26-0.56-37.320.323.994.80-18.60
Shares Outstanding517.35517.00516.45514.28513.95513.50513.08510.93
Market Capitalization13,668.3311,011.128,643.439,823.6111,695.1515,538.9417,557.3914,888.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,968.001,766.003,082.001,722.002,956.003,736.003,335.001,838.003,394.00
Short Term Receivables1,932.001,730.001,772.002,623.002,713.002,077.001,896.001,840.001,793.00
Inventories2,232.002,046.001,918.002,679.002,453.001,916.001,653.001,667.001,475.00
Other Current Assets740.003,311.002,828.00987.00750.00682.00619.00614.00601.00
Total Current Assets6,872.008,853.009,600.008,011.008,872.008,411.007,503.005,959.007,263.00
Net Property, Plant & Equipment3,186.003,176.003,207.005,236.005,808.005,325.005,120.004,530.004,588.00
Total Investments and Advances103.00109.00136.00247.00154.00135.0086.0045.0047.00
Long-Term Note Receivable126.00132.00154.00211.00224.00222.00231.00176.00187.00
Intangible Assets9,298.0010,498.0011,711.0013,245.0017,628.004,888.004,501.004,412.004,473.00
Deferred Tax Assets200.00204.00263.00280.00376.00748.00621.00483.00408.00
Other Assets270.002,810.003,205.001,057.00459.00290.00131.00115.00145.00
Total Assets20,055.0025,782.0028,276.0028,287.0033,521.0020,019.0018,193.0015,720.0017,111.00
Short Term Debt Incl. Current Port. of LT Debt84.002,832.002,759.001,524.00639.00517.00642.004.003.00
Accounts Payable999.00968.00881.001,110.001,246.001,043.00892.00998.00920.00
Income Tax Payable83.00121.0078.0091.0090.00135.0085.00104.0085.00
Other Current Liabilities1,804.002,590.002,785.002,020.002,261.001,638.001,611.001,708.001,813.00
Total Current Liabilities2,970.006,511.006,503.004,745.004,236.003,333.003,230.002,814.002,821.00
Long Term Debt9,696.0010,617.0011,354.0015,679.0017,671.006,287.005,319.003,481.003,509.00
Provision for Risks Charges674.00717.00747.00873.001,092.001,264.001,299.001,129.001,250.00
Deferred Tax Liabilities245.00103.00403.00661.00962.00143.00192.00215.00280.00
Other Liabilities368.00810.00801.00434.00439.00266.00241.00215.00135.00
Total Liabilities13,953.0018,758.0019,808.0022,392.0024,400.0011,293.0010,281.007,854.007,995.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6,129.006,964.008,402.005,833.009,077.008,689.007,882.007,844.009,124.00
Total Shareholders Equity6,129.006,964.008,402.005,833.009,077.008,689.007,882.007,844.009,124.00
Accumulated Minority Interest-27.0060.0066.0062.0044.0037.0030.0022.00-8.00
Total Equity6,102.007,024.008,468.005,895.009,121.008,726.007,912.007,866.009,116.00
Total Liabilities & Stockholders Equity20,055.0025,782.0028,276.0028,287.0033,521.0020,019.0018,193.0015,720.0017,111.00
Book Value Per Share11.9213.6316.5511.6318.1017.2115.5715.2916.85
Tangible Book Value Per Share-6.16-6.92-6.52-14.78-17.057.536.686.698.59
Full-Time Employees37,50038,00060,00060,00060,00050,00050,00050,00047,000
Price to Book Ratio2.101.892.424.644.744.665.374.333.72
Return on Assets-3.93-1.250.62-8.634.805.775.929.454.43
Return on Equity-13.75-4.392.44-35.7614.4513.3012.7718.298.32
Return on Invested Capital-6.66-3.69-1.14-11.314.807.367.5813.655.66
Quick Ratio1.561.051.181.121.521.951.811.532.05
Current Ratio2.311.361.481.692.092.522.322.122.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-619.00-900.00-326.00181.00-2,421.001,295.001,110.001,011.001,546.00
Depreciation955.00981.00997.00984.001,380.00890.00823.00789.00771.00
Other Funds (Non Cash)649.00795.00846.00656.003,423.00344.00295.001,039.00211.00
Funds from Operations1,138.00953.001,255.001,565.002,152.002,383.002,140.002,529.002,265.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital502.00-108.00-236.00161.00-941.00-161.00-272.00-425.00-248.00
Cash from Operating Activities1,640.00845.001,019.001,726.001,211.002,222.001,868.002,104.002,017.00
Capital Expenditures-506.00-522.00-446.00-432.00-620.00-743.00-709.00-696.00-659.00
Net Assets From Acquisitions0.000.00-14.00-4.00-263.00-10,502.00-494.00-418.00-268.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.0034.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.0034.000.000.000.000.000.000.00
Other Uses0.000.00-216.000.00-59.000.000.000.000.00
Other Sources-52.003,363.0016.003,649.0011.0045.0024.0014.0011.00
Cash from Investing Activities-558.002,841.00-626.003,213.00-931.00-11,200.00-1,179.00-1,100.00-916.00
Cash Dividends Paid-102.00-348.00-590.00-586.00-573.00-530.00-473.00-423.00-376.00
Change in Capital Stock24.0030.0071.0095.0095.00-413.00-298.00-914.00-2,194.00
Repurchase of Common Pref Stock0.000.000.000.00-32.00-600.00-500.00-1,270.00-2,452.00
Sale of Common Pref Stock24.0030.0071.0095.00127.00187.00202.00356.00258.00
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-586.00-3,791.00-531.00-2,935.00-899.009,228.00478.001,883.000.00
Change in Long Term Debt-586.00-3,491.00-2,657.00-2,634.00-954.008,982.00704.001,883.000.00
Issuance of Long Term Debt1,998.001,998.000.000.000.0011,805.001,885.001,883.000.00
Reduction of Long Term Debt-2,584.00-5,489.00-2,657.00-2,634.00-954.00-2,823.00-1,181.000.000.00
Net Financing Active Other Cash Flow-145.00-107.00-31.00-63.00-61.00-40.00-52.00-48.00-33.00
Other Financing Activities Uses-145.00-107.00-31.00-63.00-61.00-40.00-52.00-48.00-33.00
Cash from Financing Activities-809.00-4,216.00-1,081.00-3,489.00-1,438.008,245.00-345.00498.00-2,603.00
Exchange Rate Effect-20.0084.00-96.0026.00-76.00-47.0057.00-5.00-63.00
Net Change in Cash253.00-446.00-784.001,476.00-1,234.00-780.00401.001,497.00-1,565.00
Free Cash Flow1,137.00332.00573.001,294.00591.001,479.001,159.001,408.001,358.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow12.06--27.631,427.1645.9560.4744.0636.60
Deferred Taxes & Investment Tax Credit-77.00-262.00-256.00-230.00-146.00-88.00-310.00-263.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,975.002,150.002,017.001,968.001,726.001,686.00
Short Term Receivables1,845.001,985.001,768.001,932.001,842.001,828.00
Inventories2,300.002,259.002,316.002,232.002,460.002,384.00
Other Current Assets706.00595.00746.00740.00905.00851.00
Total Current Assets6,826.006,989.006,847.006,872.006,933.006,749.00
Net Property, Plant & Equipment3,133.003,174.003,190.003,186.003,082.003,091.00
Total Investments and Advances51.0051.0047.00103.0053.0040.00
Intangible Assets8,798.008,959.009,117.009,298.0010,205.0010,345.00
Deferred Tax Assets---200.00--
Other Assets557.00560.00579.00270.00721.00747.00
Total Assets19,414.0019,791.0019,846.0020,055.0021,067.0021,046.00
Short Term Debt Incl. Current Port. of LT Debt844.00844.00842.0084.00755.008.00
Accounts Payable1,024.001,034.001,086.00999.00953.00995.00
Income Tax Payable---83.00--
Other Current Liabilities1,941.001,713.001,765.001,804.002,067.001,936.00
Total Current Liabilities3,809.003,591.003,693.002,970.003,775.002,939.00
Long Term Debt7,168.008,013.008,845.009,696.008,957.009,717.00
Provision for Risks Charges0.000.000.00674.000.000.00
Deferred Tax Liabilities---245.00--
Other Liabilities1,962.002,008.001,292.00368.001,121.001,097.00
Total Liabilities12,939.0013,612.0013,830.0013,953.0013,853.0013,753.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6,502.006,206.006,043.006,129.007,241.007,320.00
Total Shareholders Equity6,502.006,206.006,043.006,129.007,241.007,320.00
Accumulated Minority Interest-27.00-27.00-27.00-27.00-27.00-27.00
Total Equity6,475.006,179.006,016.006,102.007,214.007,293.00
Total Liabilities & Stockholders Equity19,414.0019,791.0019,846.0020,055.0021,067.0021,046.00
Book Value Per Share12.5712.0011.7011.9214.0914.26
Tangible Book Value Per Share-4.44-5.32-5.95-6.16-5.77-5.89
Full-Time Employees---37,500--
Price to Book Ratio2.101.821.411.361.602.19
Return on Assets-3.06-4.74-4.77-3.93-1.49-1.04
Return on Equity-9.01-14.31-14.95-13.75-4.70-3.30
Return on Invested Capital2.150.89-0.10-7.010.060.66
Quick Ratio1.191.321.231.561.181.49
Current Ratio1.791.951.852.311.842.30

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income298.00135.00-17.00-1,035.00-51.00122.00
Depreciation239.00239.00237.00240.00237.00257.00
Other Funds (Non Cash)-183.0026.0019.00787.0029.0043.00
Funds from Operations320.00366.00268.00184.00265.00399.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital238.00-81.00-55.00400.00-28.00-182.00
Cash from Operating Activities558.00285.00213.00584.00237.00217.00
Capital Expenditures-110.00-119.00-137.00-140.00-111.00-149.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.002.00
Other Sources0.002.004.00-58.000.0032.00
Cash from Investing Activities-110.00-117.00-133.00-198.00-111.00-115.00
Cash Dividends Paid-5.00-5.00-5.00-87.00-87.00-87.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.005.008.005.009.006.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.005.008.005.009.006.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-600.000.000.0014.000.00-680.00
Change in Long Term Debt-600.000.000.0014.000.00-680.00
Issuance of Long Term Debt0.000.000.001,998.000.000.00
Reduction of Long Term Debt-600.000.000.00-1,984.000.00-680.00
Net Financing Active Other Cash Flow-21.00-31.00-14.00-79.00-3.00-1.00
Other Financing Activities Uses-21.00-31.00-14.00-79.00-3.00-1.00
Cash from Financing Activities-620.00-31.00-11.00-147.00-81.00-762.00
Exchange Rate Effect-3.000.00-18.001.00-5.0052.00
Net Change in Cash-175.00137.0051.00240.0040.00-608.00
Free Cash Flow448.00169.0076.00444.00126.0077.00
Price to Free Cash Flow12.0617.5018.93---

Revenue breakdown

Advanced Surgery2024: 1.10B 2025: 1.20B
Care and Connectivity Solutions2024: 1.81B 2025: 1.91B
Consolidation, Policy2024: 67.00M 2025: 381.00M
Front line care2024: 1.14B 2025: 1.16B
Infusion Therapies and Technologies2024: 4.10B 2025: 4.10B
Injectables and Anesthesia2024: 1.37B 2025: 1.35B
Pharmaceutical Compounding2024: 1.04B 2025: 1.14B
Eastern Europe, Middle East, Africa, Latin America, Asia2024: 1.35B 2025: 1.39B
United States2024: 5.85B 2025: 6.12B
Western Europe, Canada, Japan, Australia and New Zealand2024: 3.44B 2025: 3.73B
Consolidation, Policy2024: 67.00M 2025: 381.00M
Healthcare Systems and Technologies2024: 2.95B 2025: 3.07B
Medical Products And Therapies2024: 5.21B 2025: 5.30B
Pharmaceuticals2024: 2.41B 2025: 2.49B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.61%23.7M514.0M6.64M
2026-10-154.63%23.8M513.7M6.55M
2026-09-304.74%24.4M513.7M6.56M
2026-09-154.52%23.2M513.7M6.35M
2026-08-314.53%23.3M513.7M6.64M
2026-08-144.66%23.9M513.7M7.00M
2026-07-316.38%32.7M512.1M6.91M
2026-07-157.20%36.8M511.5M7.12M
2026-06-307.54%38.6M511.5M7.27M
2026-06-158.15%41.7M511.3M7.70M
2026-05-298.29%42.4M511.5M8.21M
2026-05-157.89%40.4M511.6M8.86M
2026-04-306.86%35.1M511.2M9.72M
2026-04-157.34%37.5M511.4M9.57M
2026-03-317.91%40.3M509.6M10.19M
2026-03-137.40%37.7M509.6M9.71M
2026-02-277.53%38.4M509.6M9.41M
2026-02-138.37%42.6M509.6M8.91M
2026-01-306.95%35.6M511.8M8.62M
2026-01-156.60%33.8M511.8M8.49M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call14.000.000.0011.98-3260.00---
call15.000.000.0011.00-3290.00---
call16.000.000.0010.00-4.000.00---
call17.000.000.009.12-3.000.00---
call18.000.000.008.19-3.000.00---
call18.500.000.007.46-6.000.00---
call19.000.000.007.17-4.000.00---
call19.500.000.006.58-3.000.00---
call20.000.000.006.18-3.000.00---
call20.500.000.005.66-2.000.00---
call21.000.000.005.10-4.000.00---
call21.500.000.004.46-1.000.00---
call22.000.000.004.03-3.000.00---
call22.500.000.003.54-19.000.00---
call23.000.000.003.11-3.000.00---
call23.500.000.002.48-7.000.00---
call24.000.000.002.22-37.000.00---
call24.500.000.000.00-0.000.00---
call25.000.000.001.69-1090.00---
call25.500.000.000.87-93.000.00---
call26.000.000.000.55-28.000.00---
call27.000.000.000.19-2280.00---
call28.000.000.000.04-48.000.00---
call29.000.000.000.25-12.000.00---
call30.000.000.000.05-4.000.00---
call31.000.000.000.00-0.000.00---
call32.000.000.000.00-0.000.00---
call33.000.000.000.00-0.000.00---
call34.000.000.000.00-0.000.00---
call35.000.000.000.00-0.000.00---
call36.000.000.000.00-0.000.00---
put14.000.000.000.00-0.000.00---
put15.000.000.000.36-2.000.00---
put16.000.000.000.65-1.000.00---
put17.000.000.000.00-0.000.00---
put18.000.000.000.00-0.000.00---
put18.500.000.000.00-0.000.00---
put19.000.000.000.00-0.000.00---
put19.500.000.000.00-0.000.00---
put20.000.000.000.32-1.000.00---
put20.500.000.000.00-0.000.00---
put21.000.000.000.40-61.000.00---
put21.500.000.000.20-30.000.00---
put22.000.000.000.30-40.000.00---
put22.500.000.000.50-2.000.00---
put23.000.000.000.12-71.000.00---
put23.500.000.000.00-0.000.00---
put24.000.000.000.05-1120.00---
put24.500.000.000.10-2.000.00---
put25.000.000.000.25-31.000.00---
put25.500.000.000.20-16.000.00---
put26.000.000.000.25-34.000.00---
put27.000.000.001.40-3.000.00---
put28.000.000.003.24-1.000.00---
put29.000.000.000.00-0.000.00---
put30.000.000.000.00-0.000.00---
put31.000.000.000.00-0.000.00---
put32.000.000.000.00-0.000.00---
put33.000.000.000.00-0.000.00---
put34.000.000.009.05-0.000.00---
put35.000.000.0011.75-0.000.00---
put36.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-28SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-023Initial statement of beneficial ownership of securities2026-10-01SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-15SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-198-KCurrent report2026-08-18SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-048-KCurrent report2026-07-31SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-06-05SCHEDULE 13G/ASEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-18144Filing for proposed sale of securities under Rule 144.SEC
2026-05-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-088-KCurrent report2026-05-04SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.15.85%
PZENA INVESTMENT MANAGEMENT LLC12.07%
DODGE & COX11.30%
FMR LLC9.95%
VANGUARD CAPITAL MANAGEMENT LLC6.54%
VANGUARD PORTFOLIO MANAGEMENT LLC4.66%
STATE STREET CORP3.99%
GEODE CAPITAL MANAGEMENT, LLC2.69%
GREENHAVEN ASSOCIATES INC2.40%
Invesco Ltd.2.39%

Funds

Fund% owned
Lord Abbett Short Duration Income Fund16.20%
Capital Group Core Bond ETF12.06%
Baird Aggregate Bond Fund10.47%
American Funds Multi-Sector Income Fund9.99%
Lord Abbett Ultra Short Bond Fund7.66%
VANGUARD SHORT-TERM INVESTMENT-GRADE FUND7.55%
Dodge & Cox Stock Fund7.48%
Baird Core Plus Bond Fund6.26%
State Street(R) SPDR(R) Portfolio Short Term Corporate Bond ETF5.18%
VANGUARD SHORT-TERM CORPORATE BOND INDEX FUND4.30%

OakChart. BAX. Cached 15 minutes.